SAMSUNG BIOLOGICS Co., Ltd. Statistics
Want to see KR:207940 full AI Analyst Report?
SAMSUNG BIOLOGICS Co., Ltd. (207940) Stock Statistics & Valuation Metrics
Total Valuation
SAMSUNG BIOLOGICS Co., Ltd. has a market cap or net worth of KRW 70.62T. The enterprise value is KRW 63.37T.
- Market Cap
- KRW 70.62T
- Enterprise Value
- KRW 63.37T
Share Statistics
SAMSUNG BIOLOGICS Co., Ltd. has 48,108,982 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 48,108,982
- Owned by Insiders
- ―
- Owned by Institutions
- 5.26%
Financial Efficiency
SAMSUNG BIOLOGICS Co., Ltd.’s return on equity (ROE) is 0.24 and return on invested capital (ROIC) is 17.81%.
- Return on Equity (ROE)
- 0.24
- Return on Assets (ROA)
- 0.16
- Return on Invested Capital (ROIC)
- 17.81%
- Return on Capital Employed (ROCE)
- 0.24
- Revenue Per Employee
- 835.38M
- Profits Per Employee
- 327.10M
- Employee Count
- 5,455
- Asset Turnover
- 0.41
- Inventory Turnover
- 0.97
Valuation Ratios
The current PE Ratio of SAMSUNG BIOLOGICS Co., Ltd. is 36.54. SAMSUNG BIOLOGICS Co., Ltd.’s PEG ratio is 2.86.
- PE Ratio
- 36.54
- PS Ratio
- 15.11
- PB Ratio
- 7.92
- Price to FCF
- 41.13
- Price to Operating Cash Flow
- 27.20
- PEG Ratio
- 2.86
Income Statement
In the last 12 months, SAMSUNG BIOLOGICS Co., Ltd. had revenue of 4.56T and earned 1.78T in profits. Earnings per share was 38588.00.
- Revenue
- 4.56T
- Gross Profit
- 2.48T
- Operating Income
- 2.07T
- Pretax Income
- 2.12T
- Net Income
- 1.78T
- EBITDA
- 2.78T
- Earnings Per Share (EPS)
- 38588.00
Cash Flow
In the last 12 months, operating cash flow was 2.43T and capital expenditures -826.23B, giving a free cash flow of 1.61T billion.
- Operating Cash Flow
- 2.43T
- Free Cash Flow
- 1.61T
- Free Cash Flow per Share
- 34496.38
Dividends & Yields
SAMSUNG BIOLOGICS Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.42%
- Earnings Yield
- 2.70%
Stock Price Statistics
- Beta
- 0.14
- 52-Week Price Change
- -23.31%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 54.72
- Average Volume (3m)
- 59.70K
Important Dates
SAMSUNG BIOLOGICS Co., Ltd. upcoming earnings date is Jan 27, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 21, 2026
- Next Earnings Date
- Jan 27, 2027
- Ex-Dividend Date
- ―
Financial Position
SAMSUNG BIOLOGICS Co., Ltd. as a current ratio of 1.74, with Debt / Equity ratio of 12.46%
- Current Ratio
- 1.74
- Quick Ratio
- 0.90
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.28
- Interest Coverage Ratio
- 70.93
Taxes
In the past 12 months, SAMSUNG BIOLOGICS Co., Ltd. has paid 504.30B in taxes.
- Income Tax
- 504.30B
- Effective Tax Rate
- 0.24
Enterprise Valuation
SAMSUNG BIOLOGICS Co., Ltd. EV to EBITDA ratio is 26.69, with an EV/FCF ratio of 42.00.
- EV to Sales
- 15.43
- EV to EBITDA
- 26.69
- EV to Free Cash Flow
- 42.00
- EV to Operating Cash Flow
- 27.74
Balance Sheet
SAMSUNG BIOLOGICS Co., Ltd. has KRW 2.19T in cash and marketable securities with KRW 1.24T in debt, giving a net cash position of KRW 947.30B billion.
- Cash & Marketable Securities
- KRW 2.19T
- Total Debt
- KRW 1.24T
- Net Cash
- KRW 947.30B
- Net Cash Per Share
- KRW 19.69K
- Tangible Book Value Per Share
- KRW 178.98K
Margins
Gross margin is 68.56%, with operating margin of 43.37%, and net profit margin of 41.15%.
- Gross Margin
- 68.56%
- Operating Margin
- 43.37%
- Pretax Margin
- 50.28%
- Net Profit Margin
- 41.15%
- EBITDA Margin
- 57.79%
- EBIT Margin
- 50.49%
Analyst Forecast
The average price target for SAMSUNG BIOLOGICS Co., Ltd. is KRW 1.55M, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- KRW 1.55M
- Price Target Upside
- 8.39% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 1
- Revenue Growth Forecast
- -20.49%
- EPS Growth Forecast
- 12.95%
Scores
- Smart Score
- ―
- AI Score
- 70
